Kala Bio (KALA) Treasury Shares (2016 - 2026)
Kala Bio (KALA) posted Treasury Shares of $417.0 for Q1 2026, down 99.78% sequentially from $186463.0 in Q4 2025, and down 99.93% YoY from $595234.0 in Q1 2025.
Kala Bio (KALA) Treasury Shares (2016 - 2026) Analysis & Trends
Kala Bio has reported Treasury Shares for 9 years, with the latest figure at $417.0 in Q1 2026.
- Quarterly Treasury Shares fell 99.93% year-over-year to $417.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $417.0 (down 99.93% YoY) and the FY2025 annual result came in at $186463.0, down 65.73% from the prior year.
- Treasury Shares slipped to $417.0 in Q1 2026 per KALA's latest filing, from $186463.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $1.1 million in Q1 2022 and troughed at $417.0 in Q1 2026.
- A 5-year average of $546595.6 and a median of $573917.0 in 2024 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2023 and 2026: Treasury Shares soared 1030.56% in 2023, then plunged 99.93% in 2026.
- Over 5 years, Treasury Shares stood at $73208.0 in 2022, then surged by 1026.92% to $824998.0 in 2023, then sank by 34.05% to $544117.0 in 2024, then slumped by 65.73% to $186463.0 in 2025, then slumped by 99.78% to $417.0 in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $417.0, $186463.0, and $383817.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.72 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 8.96 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 417.00 |
| Mar 31, 2026 | 417.00 |
| Dec 31, 2025 | 186,463.00 |
| Dec 31, 2025 | 186,463.00 |
| Sep 30, 2025 | 383,817.00 |
| Sep 30, 2025 | 383,817.00 |
| Jun 30, 2025 | 383,817.00 |
| Jun 30, 2025 | 383,817.00 |
| Mar 31, 2025 | 595,234.00 |
| Mar 31, 2025 | 595,234.00 |
| Dec 31, 2024 | 544,117.00 |
| Dec 31, 2024 | 544,117.00 |
| Sep 30, 2024 | 564,323.00 |
| Sep 30, 2024 | 564,323.00 |
| Jun 30, 2024 | 583,511.00 |
| Jun 30, 2024 | 583,511.00 |
| Mar 31, 2024 | 841,235.00 |
| Mar 31, 2024 | 841,235.00 |
| Dec 31, 2023 | 824,998.00 |
| Dec 31, 2023 | 824,998.00 |